Compare · BIIB vs TSBX
BIIB vs TSBX
Side-by-side comparison of Biogen Inc. (BIIB) and Turnstone Biologics Corp. (TSBX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and TSBX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB carries a market cap of $28.68B.
- Over the past year, BIIB is up 48.8% and TSBX is down 1.4% - BIIB leads by 50.3 points.
- BIIB has hit the wire 11 times in the past 4 weeks while TSBX has been quiet.
- BIIB has more recent analyst coverage (25 ratings vs 6 for TSBX).
- Company
- Biogen Inc.
- Turnstone Biologics Corp.
- Price
- $198.06+1.93%
- $0.36+1.63%
- Market cap
- $28.68B
- -
- 1M return
- -0.68%
- -3.58%
- 1Y return
- +48.85%
- -1.44%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 6
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest BIIB
- Biogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: Biogen Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Biogen upgraded by Needham with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
- EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
- Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
- UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
Latest TSBX
- SEC Form 15-12G filed by Turnstone Biologics Corp.
- SEC Form 4 filed by Director Orbimed Advisors Llc
- Amendment: SEC Form SCHEDULE 13D/A filed by Turnstone Biologics Corp.
- SEC Form 4 filed by Large owner Versant Ventures V, Llc
- SEC Form S-8 POS filed by Turnstone Biologics Corp.
- SEC Form S-8 POS filed by Turnstone Biologics Corp.
- Turnstone Biologics Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant
- Amendment: SEC Form SC 14D9/A filed by Turnstone Biologics Corp.
- SEC Form 25-NSE filed by Turnstone Biologics Corp.
- Amendment: SEC Form SC TO-T/A filed by Turnstone Biologics Corp.